Syndax Pharmaceuticals (SNDX) Operating Expenses (2015 - 2026)

Syndax Pharmaceuticals' Operating Expenses history runs 12 years deep, the most recent figure standing at $99.1 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 4.56% year-over-year to $99.1 million; the TTM figure through Mar 2026 stood at $441.0 million (up 13.75% YoY), while the FY2025 annual figure was $445.4 million, up 22.59% from the prior year.
• Operating Expenses was $99.1 million for Q1 2026 at Syndax Pharmaceuticals, down from $131.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $131.3 million in Q4 2025 to a low of $35.1 million in Q3 2022.
• Historically, Operating Expenses has averaged $75.9 million across 5 years, with a median of $77.9 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Operating Expenses soared 85.34% in 2023, then declined 4.56% in 2026.
• A 5-year view of Operating Expenses shows it stood at $42.0 million in 2022, then jumped by 85.34% to $77.9 million in 2023, then jumped by 33.55% to $104.0 million in 2024, then advanced by 26.17% to $131.3 million in 2025, then dropped by 24.54% to $99.1 million in 2026.
• The last three Operating Expenses figures came in at $99.1 million (Q1 2026), $131.3 million (Q4 2025), and $103.3 million (Q3 2025), per Business Quant data.